Switch theme
Sign up to access all valuation multiples
Anatolia Tani Ve Biyoteknoloji Urunleri Arastirma Gelistirme Sanayi Ve Ticaret AS is an international biotechnology company. It is engaged in designing, developing, and manufacturing Real-Time PCR kits, nucleic acid extraction kits, and automated nucleic acid extraction instruments. It also manufactures NA Extraction kits, Microbiology kits, Genetic Disorders kits, Panel kits, Sequencing kits, Food Testing kits.
2010
n/a
Last FY Revenue $13.6M
Last FY EBITDA -$1.4M
$53.9M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Anatolia Geneworks achieved revenue of $13.6M and an EBITDA of -$1.4M.
Anatolia Geneworks expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Anatolia Geneworks valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $13.6M | XXX | XXX | XXX |
| Gross Profit | XXX | $8.6M | XXX | XXX | XXX |
| Gross Margin | XXX | 63% | XXX | XXX | XXX |
| EBITDA | XXX | -$1.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -11% | XXX | XXX | XXX |
| EBIT | XXX | $0.4M | XXX | XXX | XXX |
| EBIT Margin | XXX | 3% | XXX | XXX | XXX |
| Net Profit | XXX | -$5.6M | XXX | XXX | XXX |
| Net Margin | XXX | -41% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Anatolia Geneworks's stock price is TRY 11 (or $0).
Anatolia Geneworks has current market cap of TRY 2.3B (or $59.1M), and EV of TRY 2.1B (or $53.9M).
See Anatolia Geneworks trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $53.9M | $59.1M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Anatolia Geneworks has market cap of $59.1M and EV of $53.9M.
Anatolia Geneworks's trades at 4.0x EV/Revenue multiple, and -37.7x EV/EBITDA.
Equity research analysts estimate Anatolia Geneworks's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Anatolia Geneworks's P/E ratio is not available.
See valuation multiples for Anatolia Geneworks and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $59.1M | XXX | $59.1M | XXX | XXX | XXX |
| EV (current) | $53.9M | XXX | $53.9M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -37.7x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 121.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -10.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -20.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAnatolia Geneworks's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Anatolia Geneworks's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Anatolia Geneworks's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Anatolia Geneworks and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -11% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 10% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Anatolia Geneworks acquired XXX companies to date.
Last acquisition by Anatolia Geneworks was XXXXXXXX, XXXXX XXXXX XXXXXX . Anatolia Geneworks acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Anatolia Geneworks founded? | Anatolia Geneworks was founded in 2010. |
| Where is Anatolia Geneworks headquartered? | Anatolia Geneworks is headquartered in Turkey. |
| Is Anatolia Geneworks publicy listed? | Yes, Anatolia Geneworks is a public company listed on IST. |
| What is the stock symbol of Anatolia Geneworks? | Anatolia Geneworks trades under ANGEN ticker. |
| When did Anatolia Geneworks go public? | Anatolia Geneworks went public in 2021. |
| Who are competitors of Anatolia Geneworks? | Similar companies to Anatolia Geneworks include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Anatolia Geneworks? | Anatolia Geneworks's current market cap is $59.1M |
| Is Anatolia Geneworks profitable? | Yes, Anatolia Geneworks is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
